Twist Bioscience Ranked 60th Fastest Growing Company in North America on Deloitte’s 2020 Fast 500™
November 18 2020 - 7:00AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), today announced
that it ranked 60th on Deloitte’s Technology Fast 500™, a ranking
of the 500 fastest-growing technology, media, telecommunications,
life sciences and energy tech companies in North America now in its
26th year.
“The entire team at Twist has been working very hard to innovate
and execute, offering synthetic DNA and DNA products to enable our
customers to improve health and sustainability,” said Emily M.
Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Our
continuous drive to deliver high-quality products with exceptional
service is key to our growth and we are pleased to be recognized by
Deloitte for our rapid advancements.”
“For more than 25 years, we’ve been honoring companies that
define the cutting edge and this year’s Technology Fast 500 list is
proof positive that technology — from software and digital media
platforms, to biotech — truly does permeate so many facets of our
lives,” said Paul Silverglate, vice chairman, Deloitte LLP and U.S.
technology sector leader. “We congratulate this year’s winners,
especially during a time when innovation is needed more than ever
to address the monumental challenges posed by the pandemic.”
“Each year the Technology Fast 500 listing validates how
important technology innovation is to our daily lives. It was
interesting to see this year that while software companies
continued to dominate, biotech companies rose to the top of the
winners list for the first time, demonstrating that new categories
of innovation are accelerating in the pursuit of making life
easier, safer and more productive,” said Mohana Dissanayake,
partner, Deloitte & Touche LLP, and industry leader for
technology, media and telecommunications, within Deloitte’s audit
and assurance practice. “We extend sincere congratulations to these
well-deserved winners — who all embody a spirit of curiosity, and a
never-ending commitment to making technology advancements
possible.”
About Deloitte’s 2020 Technology Fast 500™
Now in its 26th year, Deloitte’s Technology Fast 500 provides a
ranking of the fastest-growing technology, media,
telecommunications, life sciences and energy tech companies — both
public and private — in North America. Technology Fast 500 award
winners are selected based on percentage fiscal year revenue growth
from 2016 to 2019.
In order to be eligible for Technology Fast 500 recognition,
companies must own proprietary intellectual property or technology
that is sold to customers in products that contribute to a majority
of the company’s operating revenues. Companies must have base-year
operating revenues of at least $US50,000, and current-year
operating revenues of at least $US5 million. Additionally,
companies must be in business for a minimum of four years and be
headquartered within North America.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology could make the products Twist
Bioscience is developing obsolete or non-competitive; scientific
unknowns and new information relating to the SARS-CoV-2 virus; the
duration, extent and impact of the COVID-19 pandemic; supply chain
and other disruptions caused by the COVID-19 pandemic or otherwise;
uncertainties of the retention of a significant customer; risks of
third party claims alleging infringement of patents and proprietary
rights or seeking to invalidate Twist Bioscience’s patents or
proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies.
For a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on August
12, 2020. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Twist Bioscience
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201118005544/en/
Contacts for Twist Bioscience: Investor Contact: Argot
Partners Maeve Conneighton 212-600-1902 maeve@argotpartners.com
Media Contact: Angela Bitting 925- 202-6211
media@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024